We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 24 Jun 2026

Acute inflammation and infection demand rapid production of innate immune cells, a process known as emergency myelopoiesis. More...

When dysregulated, this response can drive chronic inflammation, accelerate aging, and contribute to blood cancers. Understanding how the program is activated and sustained has been a longstanding gap with diagnostic and therapeutic implications. New findings demonstrate a single molecular “switch” that initiates emergency myelopoiesis and links it to acute myeloid leukemia.

Columbia University Irving Medical Center investigators identified a unifying activation mechanism for emergency myelopoiesis and introduced two computational resources, HemaScribe and HemaScape, developed to decode the hematopoietic response at single-cell resolution. The work reveals a common pathway—functioning as an “on” switch—that enables rapid myeloid cell production across diverse physiological insults. The discovery suggests that targeting this shared trigger could help address the overactive state that accelerates aging and fuels malignancy.

The team leveraged single-cell RNA sequencing to capture transcriptional states across tens of thousands of hematopoietic cells and paired these data with new analytics. HemaScribe provides a unified transcript-based classification to standardize cell identities, while HemaScape maps predicted developmental relationships from stem cells to mature lineages. Using these tools, the investigators visualized how emergency activation remodels hematopoiesis and pinpointed the single activation switch.

In translational analyses, cells from many patients with acute myeloid leukemia (AML) displayed a transcriptional signature indicating the emergency program was already engaged, and patients harboring this signature had worse prognosis. The study is published in Cell Stem Cell on June 18. 

The authors note that HemaScribe and HemaScape are freely available to the research community and are already being used to accelerate related projects. With these resources, investigators anticipate applying artificial intelligence to predict drug targets and uncover additional biology embedded in large single-cell datasets. The group also plans to adapt the tools to study blood aging and the restoration of normal immune cell output. 

Related Links
Columbia University Irving Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.